| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology, Hadassah University Hospital and Hebrew University Hadassah Medical School, Jerusalem, Israel 91120; and
* Department of Biological Chemistry, The Institute of Life Sciences, The Hebrew University of Jerusalem, Israel 91904
2Correspondence: The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel. E-mail: soreq{at}shum.huji.ac.il
Alternative splicing induces, under abnormal cholinergic neurotransmission, overproduction of the rare "readthrough" acetylcholinesterase variant AChE-R. We explored the pathophysiological relevance of this phenomenon in patients with myasthenia gravis (MG) and rats with experimental autoimmune MG (EAMG), neuromuscular junction diseases with depleted acetylcholine receptors. In MG and EAMG, we detected serum AChE-R accumulation. In EAMG, we alleviated electromyographic abnormalities by nanomolar doses of EN101, an antisense oligonucleotide that selectively lowers AChE-R in blood and muscle yet leaves unaffected the synaptic variant AChE-S. Whereas animals treated with placebo or conventional anticholinesterases continued to deteriorate, a 4 wk daily oral administration of EN101 improved survival, neuromuscular strength and clinical status in moribund EAMG rats. The efficacy of targeting only one AChE splicing variant highlights potential advantages of mRNA-targeted therapeutics for chronic cholinergic malfunctioning.—Brenner, T., Hamra-Amitay, Y., Evron, T., Boneva, N., Seidman, S., Soreq, H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis.
Key Words: neuromuscular function • MG • acetylcholine
This article has been cited by other articles:
|
|
 |
|
  J. D. SUSSMAN, Z. ARGOV, D. MCKEE, E. HAZUM, S. BRAWER, and H. SOREQ Antisense Treatment for Myasthenia Gravis: Experience with Monarsen Ann. N.Y. Acad. Sci., June 1, 2008; 1132(1): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Golomb Acetylcholinesterase inhibitors and Gulf War illnesses PNAS, March 18, 2008; 105(11): 4295 - 4300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Evron, B. C. Geyer, I. Cherni, M. Muralidharan, J. Kilbourne, S. P. Fletcher, H. Soreq, and T. S. Mor Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath FASEB J, September 1, 2007; 21(11): 2961 - 2969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. R. Santos, I. Vala, C. Miguel, J. T. Barata, P. Garcao, P. Agostinho, M. Mendes, A. V. Coelho, A. Calado, C. R. Oliveira, et al. Expression and Subcellular Localization of a Novel Nuclear Acetylcholinesterase Protein J. Biol. Chem., August 31, 2007; 282(35): 25597 - 25603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kaminski Restoring balance at the neuromuscular junction Neurology, August 14, 2007; 69(7): 629 - 630. [Full Text] [PDF]
|
|
|
|
|
|
Z. Argov, D. McKee, S. Agus, S. Brawer, N. Shlomowitz, O. B. Yoseph, H. Soreq, and J. D. Sussman TREATMENT OF HUMAN MYASTHENIA GRAVIS WITH ORAL ANTISENSE SUPPRESSION OF ACETYLCHOLINESTERASE Neurology, August 14, 2007; 69(7): 699 - 700. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gilboa-Geffen, P. P. Lacoste, L. Soreq, G. Cizeron-Clairac, R. Le Panse, F. Truffault, I. Shaked, H. Soreq, and S. Berrih-Aknin The thymic theme of acetylcholinesterase splice variants in myasthenia gravis Blood, May 15, 2007; 109(10): 4383 - 4391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kehat, E. Zemel, N. Cuenca, T. Evron, D. Toiber, A. Loewenstein, H. Soreq, and I. Perlman A Novel Isoform of Acetylcholinesterase Exacerbates Photoreceptors Death after Photic Stress Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1290 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. DORI and H. SOREQ Neuromuscular Therapeutics by RNA-Targeted Suppression of ACHE Gene Expression Ann. N.Y. Acad. Sci., October 1, 2006; 1082(1): 77 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Madill Chronic Fatigue Syndrome and the Cholinergic Hypothesis JAMA, December 8, 2004; 292(22): 2723 - 2723. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dong, Y.-Y. Xiang, N. Farchi, W. Ju, Y. Wu, L. Chen, Y. Wang, B. Hochner, B. Yang, H. Soreq, et al. Excessive Expression of Acetylcholinesterase Impairs Glutamatergic Synaptogenesis in Hippocampal Neurons J. Neurosci., October 13, 2004; 24(41): 8950 - 8960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Meshorer, D. Toiber, D. Zurel, I. Sahly, A. Dori, E. Cagnano, L. Schreiber, D. Grisaru, F. Tronche, and H. Soreq Combinatorial Complexity of 5' Alternative Acetylcholinesterase Transcripts and Protein Products J. Biol. Chem., July 9, 2004; 279(28): 29740 - 29751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Sklan, A. Lowenthal, M. Korner, Y. Ritov, D. M. Landers, T. Rankinen, C. Bouchard, A. S. Leon, T. Rice, D. C. Rao, et al. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study PNAS, April 13, 2004; 101(15): 5512 - 5517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. X. S. Jiang, R. C. Y. Choi, N. L. Siow, H. H. C. Lee, D. C. C. Wan, and K. W. K. Tsim Muscle Induces Neuronal Expression of Acetylcholinesterase in Neuron-Muscle Co-culture: TRANSCRIPTIONAL REGULATION MEDIATED BY cAMP-DEPENDENT SIGNALING J. Biol. Chem., November 14, 2003; 278(46): 45435 - 45444. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
